These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 10865444)

  • 21. Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization.
    Boldrini L; Calcinai A; Samaritani E; Pistolesi F; Mussi A; Lucchi M; Angeletti CA; Basolo F; Fontanini G
    Br J Cancer; 2000 Aug; 83(4):480-6. PubMed ID: 10945495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Purification and further characterization of a non-tumor necrosis factor alpha or beta differentiation-inducing cytokine, P48.
    Leftwich JA; Hall RE
    Cancer Res; 1989 Aug; 49(16):4459-65. PubMed ID: 2663142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transforming growth factor-beta1 blocks in vitro cardiac myocyte depression induced by tumor necrosis factor-alpha, interleukin-1beta, and human septic shock serum.
    Kumar A; Kumar A; Paladugu B; Mensing J; Parrillo JE
    Crit Care Med; 2007 Feb; 35(2):358-64. PubMed ID: 17204997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells.
    Grund EM; Kagan D; Tran CA; Zeitvogel A; Starzinski-Powitz A; Nataraja S; Palmer SS
    Mol Pharmacol; 2008 May; 73(5):1394-404. PubMed ID: 18252806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour necrosis factor (cachectin) and other cytokines in septic shock: a review of the literature.
    Dofferhoff AS; Vellenga E; Limburg PC; van Zanten A; Mulder PO; Weits J
    Neth J Med; 1991 Aug; 39(1-2):45-62. PubMed ID: 1961351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
    Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM
    Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour necrosis factor and cancer treatment: a historical review and perspectives.
    Terlikowski SJ
    Rocz Akad Med Bialymst; 2001; 46():5-18. PubMed ID: 11780579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [TNF-alpha].
    Yamazaki M
    Gan To Kagaku Ryoho; 1994 Nov; 21(15):2679-87. PubMed ID: 7979434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Substituted xanthines, pteridinediones, and related compounds as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor alpha.
    Cottam HB; Shih H; Tehrani LR; Wasson DB; Carson DA
    J Med Chem; 1996 Jan; 39(1):2-9. PubMed ID: 8568809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment with Y-40138, a multiple cytokine production modulator, inhibits lipopolysaccharide- or tumour necrosis factor-alpha-induced production of pro-inflammatory cytokines and augments interleukin-10.
    Fukuda T; Hisadome M; Komatsu H
    J Pharm Pharmacol; 2005 Nov; 57(11):1461-6. PubMed ID: 16259779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor necrosis factor alpha: a multifaceted peptide hormone.
    Rosenblum MG; Donato NJ
    Crit Rev Immunol; 1989; 9(1):21-44. PubMed ID: 2539946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of tumour necrosis factor-alpha in dendritic cell-mediated primary mixed leucocyte reactions.
    McKenzie JL; Calder VL; Starling GC; Hart DN
    Bone Marrow Transplant; 1995 Feb; 15(2):163-71. PubMed ID: 7773205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target.
    Tracey KJ; Cerami A
    Annu Rev Med; 1994; 45():491-503. PubMed ID: 8198398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TNF-α inhibitors with anti-oxidative stress activity from natural products.
    Li J; Zhang H; Huang W; Qian H; Li Y
    Curr Top Med Chem; 2012; 12(13):1408-21. PubMed ID: 22650374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The value of failure: the discovery of TNF and its natural inhibitor erythropoietin.
    Cerami A
    J Intern Med; 2011 Jan; 269(1):8-15. PubMed ID: 21158973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From the deepest sea shelf to the uppermost kitchen cabinet shelf: the quest for novel TNF-α inhibitors.
    Folmer F; Dicato M; Diederich M
    Curr Top Med Chem; 2012; 12(13):1392-407. PubMed ID: 22650373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic potential of natural products from terrestrial plants as TNF-α antagonist.
    Verma PK; Bala M; Kumar N; Singh B
    Curr Top Med Chem; 2012; 12(13):1422-35. PubMed ID: 22650375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level.
    Fiers W
    FEBS Lett; 1991 Jul; 285(2):199-212. PubMed ID: 1649771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumour necrosis factor in surgical illness.
    McCall JL; Parry BR
    Aust N Z J Surg; 1990 Jul; 60(7):503-9. PubMed ID: 2192699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-based discovery of natural-product-like TNF-α inhibitors.
    Chan DS; Lee HM; Yang F; Che CM; Wong CC; Abagyan R; Leung CH; Ma DL
    Angew Chem Int Ed Engl; 2010 Apr; 49(16):2860-4. PubMed ID: 20235259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.